Trials / Completed
CompletedNCT00190658
Somatropin Treatment in Patients With SHOX Deficiency and Turner Syndrome
Safety and Efficacy of Humatrope in Pediatric Patients With Genetic Short Stature (SHOX Gene Defect)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 75 (planned)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 3 Years
- Healthy volunteers
- Not accepted
Summary
This clinical trial will compare the mean first year height velocity of somatropin-treated prepubertal patients with SHOX deficiency with the height velocity of a control group of untreated prepubertal patients with SHOX deficiency. Both groups will be compared to a somatropin-treated group of girls with Turner syndrome. After the second year patients in the control group have the option to receive treatment as well. All patients will optionally be treated until they achieved adult height.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Somatropin (rDNA origin) for injection |
Timeline
- Start date
- 2000-02-01
- Primary completion
- 2004-07-01
- Completion
- 2010-09-01
- First posted
- 2005-09-19
- Last updated
- 2010-12-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00190658. Inclusion in this directory is not an endorsement.